{'fraction_non_alphanumeric': 0.08568904593639576, 'fraction_numerical': 0.07862190812720848, 'mean_word_length': 3.7012448132780085, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacokinetics of a new cephalosporin, CGP 9000 (cefroxadine), in healthy volunteers.

Oral doses of 125, 250, and 500 mg of a new cephalosporin, CGP 9000 (7 beta-[D-2-amino-2-(1,4-cyclohexadienyl)-acetamido]-3-methoxy-ceph-3-em-4-carboxylic acid), given to healthy volunteers, were evaluated pharmacokinetically. The mean peak concentrations with the respective doses were 4.5 +/- 1.4, 7.7 +/- 2.7, and 12.3 +/- 4.2 microgram/ml. The maximum serum concentration occurred after 0.5-1.5 h. The amounts recovered unchanged in urine during 12 h were 96.4 +/- 5.1, 92.4 +/- 11.7 and 96.7 +/- 7.6% of the respective doses. There was straight linear kinetics with a doubling of area under the serum curve for each dose, rising from 6.1 with the lowest, through 12.1 with the middle dose to 23.6 microgram.h/ml with the highest dose. There was an apparent lag of 0.3-0.4 h before absorption. Absorption was relatively rapid, with mean absorption rate constants of 4.68-6.26 h-1. Serum half-life varied between 0.9 and 1.0 h with the different doses. The mean renal clearance values with the three doses ranged between 322 and 344 ml/min.